McKesson completes legal filings in Germany to control its Celesio AG acquisition
Consolidation creates a global pharma distributor grossing $170 billion and employing 85,000
Yesterday (Dec. 2), McKesson announced the approval by the Stuttgart Higher Regional Court of its “domination and profit and loss transfer agreement” (which means, roughly, McKesson controls Celesio and can consolidate financial reporting of the two entities), clearing the way for “our companies to operate in an integrated way, creating a global leader in pharmaceutical purchasing and distribution,” according to a statement from McKesson CEO John Hammergren. Celesio will operate as a unit of McKesson Distribution Solutions, led by Paul Julien, EVP. Celesio itself will continue to be led by Marc Own as chairman. A new Global Procurement team will now begin making purchasing arrangements with pharma manufacturers globally.
McKesson made its original bid for Celesio in October 2013 and while it won the necessary shareholder support by ponying up $8.3 billion, still owns only 76% of the company.
Unquestionably, McKesson-Celesio will be a significant player in healthcare across much of the world. McKesson is the No. 1 drug distributor in the US; Celesio both distributes in Europe and Brazil (altogether, the two companies operate in 20 countries.) They also manage a network of 12,000 owned or franchised pharmacies.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
